An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines

• DOI: 10.1016/j.vaccine.2022.01.030
• Publication Date: 2022-01-20T03:45:50Z
• Authors: Fei Liu; Canbin Feng; Shiqi Xu; Qiang Wu; Jian Tang; Yan Chen; Ruisheng Xu; Fuliang Chen; Ni Gao; Zhengzheng Xu; Shihui Gu; Yang Lan; Haibo Zhou; Xinde Hu; Xiaojing Wang
• Keywords: Pandemic; Coronavirus

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in catastrophic damage worldwide. Accordingly, the development of powerful, safe, easily accessible vaccines with long-term effectiveness is understood as an urgently needed countermeasure against this ongoing pandemic. Guided strong promise using AAVs, we here designed, optimized, and developed AAV-based (including AAV-RBD(max), AAV-RBD(wt), AAV-2xRBD, AAV-3xRBD) that elicit immune responses RBD domain SARS-CoV-2 S protein. These immunogenic have proven long-lived, near peak levels for at least six months mice. Notably, sera immunized AAV-3xRBD vaccine contains powerful neutralizing antibodies pseudovirus. Further evidence potent specific could also be elicited canines after vaccination vaccine.